HR 1143 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Medicare IVIG Access Enhancement Act of 2025
To amend title XVIII of the Social Security Act to expand coverage of the in-home administration of intravenous immune globulin under the Medicare program.
Summary
This bill would expand Medicare coverage for in-home administration of intravenous immune globulin (IVIG) therapy to include two additional conditions starting January 1, 2027: chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Currently, Medicare covers in-home IVIG administration only for primary immune deficiency diseases; the bill expands this to encompass these two neurological conditions. The bill also authorizes the Secretary of Health and Human Services to vary payment rates for IVIG administration based on whether it is being used to treat a primary immune deficiency disease or one of the newly covered conditions, with such variations to be determined through notice and comment rulemaking.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Rep. Smith, Adrian [R-NE-3] (R-NE)
2 cosponsors
Actions (2)
- Feb 7, 2025 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · house
- Feb 7, 2025 Introduced in House
More bills on these subjects (8)
Other bills that carry the most legislative subjects in common with this one (topical discovery — distinct from the procedural related bills above).
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE HOUSE OF REPRESENTATIVES
February 7, 2025
Mr. Smith of Nebraska (for himself and Mr. Garamendi) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
A BILL
To amend title XVIII of the Social Security Act to expand coverage of the in-home administration of intravenous immune globulin under the Medicare program.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Medicare IVIG Access Enhancement Act of 2025”.
SEC. 2. EXPANDING COVERAGE OF THE IN-HOME ADMINISTRATION OF INTRAVENOUS IMMUNE GLOBULIN UNDER THE MEDICARE PROGRAM.
(a) In General.—Section 1861 of the Social Security Act (42 U.S.C. 1395x) is amended—
(1) in subsection (s)(2)(Z), by inserting “(and, beginning January 1, 2027, for the treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy)” after “primary immune deficiency diseases”; and
(2) in subsection (zz), by inserting “(or, beginning January 1, 2027, with diagnosed chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy)” after “primary immune deficiency disease”.
(b) Authority for Variance in Payments.—Section 1842(o)(8) of the Social Security Act (42 U.S.C. 1395u(o)(8)) is amended by inserting “and may vary depending on whether such administration is related to treatment of a primary immune deficiency disease or the treatment of chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy (as determined appropriate by the Secretary through notice and comment rulemaking)” after “of 2012”. <all>
Comments